CAREDX INC (CDNA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for CDNA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| CDNA | Independent Director | 69 | ["Founder & Chairman, Monograph Capital Partners (2021 - Present)","Founder & Senior Managing Director, Vida Ventures (2017 - Present)","Senior Advisor & Retired Partner, TPG (2001 - Present)","Professor (Cellular and Molecular Pharmacology), University of California, San Francisco (UCSF) (1988 - 2016)","Dr. Cohen’s thought leadership in biotechnology","Investment and financial matters specific to biotechnology companies","Public company board experience including Progyny, Intellia Therapeutics and Urogen Pharma"] | ["Technology and Innovation Committee","Governance and Nominating Committee","Compensation and Human Capital Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Independent Director Age: 69 Independent Director since: 2014 Committees: Technology and Innovation Committee Professional Experience Founder & Chairman, Monograph Capital Partners (2021 - Present) Founder & Senior Managing Director, Vida Ventures (2017 - Present) Senior Advisor & Retired Partner, TPG (2001 - Present) Professor (Cellular and Molecular Pharmacology), University of California, San Francisco (UCSF) (1988 - 2016) Key Skills & Qualifications Relevant Industry Experience: Dr. Cohen s thought leadership in biotechnology as an elected member of the National Academy of Medicine of the National Academy of Sciences and fellow of the American College of Physicians, among other organizations, and experience as Professor of Cellular and Molecular Pharmacology at UCSF, is an asset to the Board in assessing the firm s strategy. Investment, Finance or Accounting Experience: As founder and Senior Managing Director of Vida Ventures and as a Partner and more recently a Senior Advisor at TPG, Dr. Cohen is well-versed in investment and financial matters specific to biotechnology companies. Public Company Board or Governance Experience: Dr. Cohen has served on multiple public boards and committees including most recently at Progyny, Intellia Therapeutics and Urogen Pharma. Other Boards Director, Kyverna Therapeutics (2020 - Present) Director, Progyny (Nasdaq: PGNY) (2019 - 2025) Director, Intellia Therapeutics (Nasdaq: NTLA) (2019 - Present) Director, Urogen Pharma (Nasdaq: URGN) (2017 - 2024) Director, Novotech (2017 - Present) Director, Tandem Diabetes (Nasdaq: TNDM) (2013 - 2019) Director, Biocryst (Nasdaq: BCRX) (2013 - 2019) Director, Five Prime Therapeutics (Nasdaq: FPRX) (2013 - 2018) Director, Veracyte (Nasdaq: VCYT) (2013 - 2019) Director, Roka Biosciences (Nasdaq: ROKA) (2014 - 2017) Director, Quintiles (NYSE: Q) (merged with IQVIA Holdings) (2013 - 2015) Director, Genomic Health (Nasdaq: GHDX) (acquired by Exact Sciences) (2005 - 2019) Director, Matrix Laboratories (2004 - 2009) Current Organizations Member, American Academy of Arts and Sciences Fellow, National Academy of Medicine Fellow, American Medical Informatics Association Previous Organizations Trustee, Autistica Fellow, American College of Physicians Member, Association of American Physicians Fellow, Western Association of Physicians Member, American Society for Clinical Investigation Education Ph.D., Oxford University M.D., Stanford University B.S., Yale University